JackMSuMD
Pediatric Hematology & Oncology • Houston, TXAssistant Professor, Pediatrics, Baylor College of Medicine
Are you Dr. Su?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6701 Fannin St
Houston, TX 77030Phone+1 832-822-4240Fax+1 832-825-4247
Summary
- Dr. Jack Su, MD is a pediatric hematologist/oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas and California. He is affiliated with Texas Children's Hospital and is an Assistant Professor at Baylor College of Medicine.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of California (San Francisco)Residency, Pediatrics, 1994 - 1997- University of California San Francisco School of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 1996 - Present
TX State Medical License 2001 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Start of enrollment: 2005 May 01
- Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Start of enrollment: 2009 Sep 01
- Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2010 Aug 09
Publications & Presentations
PubMed
- Re-programming by a six-factor-secretome in the patient tumor ecosystem during nutrient stress and drug response.M Tarek Elghetany, Jie-Ling Pan, Karthik Sekar, Angela Major, Jack Mf Su
Iscience. 2024-10-18 - 2 citationsThe cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.Mohammad H Abu-Arja, Austin L Brown, Jack M Su, M Fatih Okcu, Holly B Lindsay
Neuro-Oncology. 2024-10-03 - CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas.Lin Qi, Yuchen Du, Yulun Huang, Mari Kogiso, Huiyuan Zhang
British Journal of Cancer. 2024-07-01
Grant Support
- Study Of Valproic Acid In Pediatric Brain TumorsNational Cancer Institute2006–2009
